profit from every DKK 100 of sales.
DKK 0DKK 100
Embla Medical hf.
DKK 28.20+0.89% today
-15.6% in 1 year
1-year low DKK 25.901-year high DKK 36.40
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay DKK 21.60 for every DKK 1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Embla Medical hf. sold, what it kept, and what it did with the cash.
Sales went from $719 million in 2022 to $929 million in 2025, with $83.3 million of profit last year.
SalesProfit
Embla Medical hf. handed back 10% of the cash it generated last year.
Buybacks $10M
Free cash flow 2025$100M
Bought back its own shares$10M
Paid as dividends–
Cash vs. debt$103M vs. $542M
Embla Medical hf. vs. similar companies
Embla Medical hf. grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from DKK 100 of sales | Sales growth a year | Price per DKK 1 of profit |
|---|---|---|---|
| Embla Medical hf. | 21.6× · Fair price | ||
 Abbott Laboratories | 29.3× · Fair price | ||
 Medtronic | 27.4× · Fair price | ||
 Stryker | 38.2× · Expensive | ||
 Edwards Lifesciences | 56.1× · Expensive |
AI analysis
An AI analyst reads Embla Medical hf.'s last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 719 | 786 | 855 | 929 | |
| 440 | 486 | 535 | 579 | |
| 67 | 87 | 113 | 125 | |
| 117 | 144 | 170 | 188 | |
| 43 | 58 | 68 | 83 | |
| 0.10 | 0.14 | 0.16 | 0.20 | |
| 61.2% | 61.8% | 62.5% | 62.3% | |
| 9.3% | 11.1% | 13.2% | 13.4% | |
| 5.9% | 7.4% | 8.0% | 9.0% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,325 | 1,386 | 1,539 | 1,730 |
| Cash | 77 | 73 | 86 | 103 |
| Total debt | 481 | 468 | 500 | 542 |
| Total liabilities | 690 | 681 | 758 | 835 |
| 636 | 702 | 777 | 891 | |
| 418 | 420 | 427 | 427 | |
| 4.8% | 6.3% | 7.0% | 7.0% | |
| 6.7% | 8.3% | 8.8% | 9.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 61 | 94 | 116 | 133 | |
| 26 | 42 | 39 | 32 | |
| 35 | 52 | 77 | 100 | |
| Dividends paid | – | – | – | – |
| 10 | 0 | 0 | 10 | |
| – | – | – | – |
Valuation
- 21.6×
- –
- 0.90
- 1.9×
- 1.9×
- 17.9×
- 11.9×
- 5.6%
- 4.6%
- –
Profitability
- 62.3%
- 13.4%
- 9.0%
- –
- 6.9%
- 6.2%
- –
- –
- –
- –
Growth
- +8.9%
- +23.9%
- –
- –
- +0.7%
Financial health
- 2.3×
- 0.61
- –
- 6.5×
- 1.48
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 42%of 948
Top 39%of 871
Top 34%of 560
Bottom 42%of 868
Top 17%of 985
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
3/7Passes 3 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
57No pass
Benjamin Graham
60Pass
Philip Fisher
68Pass
Peter Lynch
72Pass
Joel Greenblatt
28No pass
Charlie Munger
42No pass
Terry Smith
47No pass
Questions about Embla Medical hf.
Is Embla Medical hf. a good stock to buy?
A solid business at a fair price. 3 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Embla Medical hf. AI analysis
What does Embla Medical hf. do?
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. It is in Medical Devices, based in Reykjavik, Iceland, with 4,500 employees.
Is Embla Medical hf. stock halal?
Yes. Embla Medical hf. passes our halal screen: its business is permitted and its debt is 5% of its market value, under the 30% limit. How we check
How has Embla Medical hf. stock done over the past year?
Down 15.6% over the past twelve months, to DKK 28.20. It traded between DKK 25.90 and DKK 36.40 and is 22.5% below its high.
Who are Embla Medical hf.'s competitors?
The largest listed companies in the same industry are Abbott Laboratories, Medtronic, Stryker and Edwards Lifesciences. The peers table on this page compares their profit, growth and price with Embla Medical hf.'s.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.